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Introduction: Cortical brain atrophy detectable with MRI in non-demented advanced Parkinson's disease
(PD) is well characterized, but its presence in early disease stages is still under debate. We aimed to
investigate cortical atrophy patterns in a large sample of early untreated PD patients using a hypothesis-
free data-driven approach.
Methods: Seventy-seven de novo PD patients and 50 controls from the Parkinson's Progression Marker
Initiative database with T1-weighted images in a 3-tesla Siemens scanner were included in this study.
Mean cortical thickness was extracted from 360 cortical areas defined by the Human Connectome Project
Multi-Modal Parcellation version 1.0, and a hierarchical cluster analysis was performed using Ward's
linkage method. A general linear model with cortical thickness data was then used to compare clustering
groups using FreeSurfer software.
Results: We identified two patterns of cortical atrophy. Compared with controls, patients grouped in
pattern 1 (n¼ 33) were characterized by cortical thinning in bilateral orbitofrontal, anterior cingulate,
and lateral and medial anterior temporal gyri. Patients in pattern 2 (n¼ 44) showed cortical thinning in
bilateral occipital gyrus, cuneus, superior parietal gyrus, and left postcentral gyrus, and they showed
neuropsychological impairment in memory and other cognitive domains.
Conclusions: Even in the early stages of PD, there is evidence of cortical brain atrophy. Neuroimaging
clustering analysis is able to detect two subgroups of cortical thinning, one with mainly anterior atrophy,
and the other with posterior predominance and worse cognitive performance.
© 2018 Elsevier Ltd. All rights reserved.1. Introduction
Impaired cognition in Parkinson's disease (PD) is often present
in untreated patients, over 20% of whom fulfill criteria for mild






b.edu (C. Junque).domains such as executive function, memory, attention, or visuo-
spatial function [1]. Advances in magnetic resonance imaging (MRI)
acquisition and analysis allowed the identification of cortical
implication in early untreated patients. Cortical thinning is present
in de novo PD patients with MCI involving frontal, temporal [2,3],
and parietal [3] regions. However, in newly diagnosed PD patients
withoutMCI, studies failed to find differences between patients and
controls [2] or found thinning in small temporal [3] or parietal [4]
cortical regions.
The heterogeneity of PD clinical phenotypes has led to increased
interest in patient subtyping [5] in an attempt to understand the
underlying mechanisms and improve prognostic accuracy. In line
C. Uribe et al. / Parkinsonism and Related Disorders 50 (2018) 3e94with these efforts, we have previously identified three subtypes
based on hierarchical cluster analysis of cortical thickness. One
subtype showed temporal and parietal involvement; another dis-
played orbitofrontal and occipital atrophy and younger disease
onset; and a third group of patients showed no detectable cortical
atrophy [6].
The Parkinson's Progression Markers Initiative (PPMI) is a
comprehensive observational, international, multicenter study
designed to identify PD progression biomarkers such as cerebral
imaging in a cohort of recently-diagnosed PD patients [7]. Recent
studies have identified Parkinson's subtypes in this cohort based on
motor and non-motor data [8,9]. However, there is no evidence
regarding subtypes based on objective structural imaging data in
early PD.
Using data from the PPMI database, we aimed to examine
cortical atrophy patterns in a large sample of newly diagnosed, drug
naïve PD patients using a hypothesis-free data-driven approach. In
light of previous results, we hypothesized that we would identify
different brain cortical atrophy patterns associated with different
clinical and neuropsychological characteristics.
2. Methods
2.1. Participants
Data used in this study were obtained from the PPMI database
[7]. For up-to-date information on the study, visit www.ppmi-info.
org. T1-weighted images acquired on 3-tesla SiemensMRI scanners
and clinical and neuropsychological data obtained from 119 PD
patients and 77HC assessed between 2010 and 2015were included.
All imaging and non-imaging data corresponded to the same time
points and were acquired prior to any L-DOPA intake. Inclusion
criteria were: (i) recent diagnosis of PD with asymmetric resting
tremor or asymmetric bradykinesia, or two of: bradykinesia, resting
tremor, and rigidity; (ii) absence of treatment for PD; (iii) neuro-
imaging evidence of significant dopamine transporter deficit
consistent with the clinical diagnosis of PD and ruling out PD look-
alike conditions such as drug-induced and vascular parkinsonism
or essential tremor; (iv) available T1-weighted images in a 3T
Siemens scanner (for both PD patients and HC) and (v) age> 50
years old (for both PD patients and HC). Exclusion criteria for all
participants were: (i) diagnosis of dementia; (ii) significant
neurologic or psychiatric dysfunction; (iii) first-degree family
member with PD, and (iv) presence of MRI motion artifacts, field
distortions, intensity inhomogeneities, or detectable brain injuries.
A total of 77 de novo PD patients and 50 HC were selected. The
following participants were excluded from the study: 4 patients
and 1 HC due to other neurological disease, 18 PD patients and 20
HC due toMRImotion artifacts at visual inspection performed by an
expert radiologist (HCB), and 18 PD patients and 5 HC due to
cortical thickness preprocessing problems (see MRI images sec-
tion). Finally, we performed an initial cluster analysis for the PD
group and another for the control group to detect possible
abnormal outliers on MRI data. From these, we discarded 2 PD
patients and 1 HC that constituted independent clusters by
themselves.
Each participating PPMI site received approval from an ethical
standards committee on human experimentation before study
initiation and obtained written informed consent for research from
all individuals participating in the study.
2.2. Clinical and neuropsychological assessments
Motor symptoms were assessed with the Movement Disorder
Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) PartIII andmotor subtypes were established based on the ratio from the
means of several items of theMDS-UPDRS Part III. Activities of daily
living (ADL) were evaluated with the Schwab and England Scale for
PD patients and MDS-UPDRS Part II for all participants. Global
cognition was assessed with the MoCA, and depressive symptoms
using the 15-item Geriatric Depression Scale (GDS-15) with a cutoff
score of 5 or more indicating clinically significant symptoms as
described in www.ppmi-info.org [7].
All subjects underwent comprehensive neuropsychological
assessment following Movement Disorder Society task force rec-
ommendations [10] (except for the absence of tests evaluating the
language domain). Memory was assessed with the Hopkins Verbal
Learning Test-Revised (HVLT-R); visuospatial function was evalu-
ated with the Benton Judgment of Line Orientation short form (15-
item version); attention and working memory through the Symbol
Digit Modalities Test and Letter-Number Sequencing; and executive
function with phonemic (letter ‘f’) and semantic (animal) verbal
fluency [11].
Initially, z scores for each test and for each subject were calcu-
lated based on the control group's means and standard deviations.
Expected z scores adjusted for age, sex, and education for each test
and each subject were calculated based on a multiple regression
analysis performed in the HC group [1]. The presence of MCI was
defined using PD-MCI diagnostic criteria level I [10]: (i) MoCA
scores as measure of global cognition below 26 [12] and/or (ii) the z
score of a given test was at least 1.5 lower than the expected score
on any 2 test scores. Impairment in each cognitive domainwas also
established if at least 1 test in the domain was impaired.
University of Pennsylvania Smell Identification Test (UPSIT)
scores were available in a subsample of 55 PD patients and 28 HC
due to missing values. The cutoff indicating anosmia was 18 or less
[13].
2.3. MRI images
All three-dimensional T1-weighted MRI scans were acquired in
the sagittal plane on 3T Siemens scanners (Erlangen, Germany) at
different centers using an MPRAGE sequence. The acquisition pa-
rameters were as follows: repetition time¼ 2300/1900ms; echo
time¼ 2.98/2.96/2.27/2.48/2.52ms; inversion time¼ 900ms; flip
angle: 9; matrix¼ 240 256/256 256; voxel¼ 1 1 1mm3.
Cortical thickness was estimated using the automated FreeSurfer
stream (version 5.1, http://surfer.nmr.harvard.edu). Detailed infor-
mation about the processing FreeSurfer stream is described in
Segura et al. [14]. After Freesurfer preprocessing, results for each
subject were visually inspected to ensure accuracy of registration,
skull stripping, segmentation, and cortical surface reconstruction.
Possible errors were fixed by manual intervention following stan-
dard procedures (https://surfer.nmr.mgh.harvard.edu/fswiki/
FsTutorial/TroubleshootingData#Fixingerrors). In addition, we
extracted the mean thickness for each of the 360 cortical areas
defined in the Human Connectome Project Multi-Modal Parcella-
tion version 1.0 (HCP-MMP1.0) [15,16].
2.4. Cluster analysis
MATLAB (release 2014b, The MathWorks, Inc., Natick, Massa-
chusetts) was used to perform an agglomerative hierarchical
cluster analysis using cortical thickness data from the 77 un-
treated PD patients. To reduce dimensionality and improve the
model's performance calculating similarity/distance measures,
mean cortical thickness values for the 360 areas from the HCP-
MMP1.0 were used as features in the cluster analysis instead of
whole-brain vertex information. To control for variations in
global atrophy between patients [6], vertices were normalized
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thickness*lh.surfarea) þ (rh.thickness*rh.surfarea))/
(lh.surfarea þ rh.surfarea).
Ward's clustering linkage method [6,17] was used to combine
pairs of clusters at each step while minimizing the sum of square
errors from the cluster mean. Each of the 77 patients was placed in
their own cluster and then progressively clustered with others.
Cluster analysis results are shown as a dendrogram (Fig. 1) and a
heatmap representing individual values for each cortical region
(Supplementary Figure 1 and Supplementary Table 1 for the order
of regions as represented in the figure).
2.5. Statistical analysis
Intergroup cortical thickness comparisons were performed us-
ing a vertex-by-vertex general linear model with FreeSurfer. The
model included cortical thickness as a dependent factor and group
as an independent factor. All results were corrected for multiple
comparisons using pre-cached cluster-wiseMonte Carlo simulation
with 10,000 iterations. Reported cortical regions reached a two-
tailed corrected significance level of p< 0.05.
Demographic, neuropsychological, and clinical statistical ana-
lyses were conducted using IBM SPSS Statistics 24.0 (2011; Armonk,
NY: IBM Corp). We tested for group differences in demographic and
clinical variables as well as in neuropsychological performance
between HC and PD patient subtypes using Kruskal-Wallis test
followed byMann-Whitney's pairwise comparisons and Bonferroni
correction for non-normally distributed quantitative measures as
indicated by the Kolmogorov-Smirnov test; for normally distrib-
uted measures, an analysis of variance (ANOVA) followed by Bon-
ferroni post hoc test was used. Pearson's chi squared tests were
used for categorical measures.
For comparisons between the collapsed PD sample and HC we
used Mann-Whitney's test or Student t-test as appropriate.
2.6. Cluster evaluation
To determine the optimal number of clusters, we computed the
Calinski-Harabasz index with MATLAB. The Calinski-Harabasz cri-
terion is best suited for cluster analysis with squared EuclideanFig. 1. Dendrogram of PD patients clustered according to mean cortical thickness in-
formation.
Abbreviations: P1 ¼ Pattern 1; P2 ¼ Pattern 2; P3 ¼ Pattern 3.distances.
The higher the ratio is, the better the cluster solution. An
optimal ratio is determined by a large between-cluster variance and




3.1. Characteristics of the PD sample
Demographic and clinical (Supplementary Table 2), neuropsy-
chological (Fig. 2a), and cortical thickness (Supplementary Figure 2,
Supplementary Table 3) differences between all PD patients and HC
are shown in Supplementary Results 1.
3.2. PD cortical thickness subtypes based on cluster analysis
We identified 2 patterns of cortical thinning compared with HC
(Fig. 3, Supplementary Table 3). Patients in pattern 1 (n¼ 33, 42.9%)
showed reduced cortical thickness in bilateral orbitofrontal, ante-
rior cingulate, and lateral and medial anterior temporal regions, as
well as a small cluster of cortical thickening in the right cuneus,Fig. 2. Neuropsychological performance. (a) Healthy controls in orange and PD
collapsed sample in blue. (b) Healthy controls in orange; Pattern 1 patients in blue and
Pattern 2 patients in green.
Data are presented as z-scores. Lower z-scores indicate worse performance.
Abbreviations: HC¼ healthy controls; HVLT total¼Hopkins Verbal Learning Test total;
HVLT delayed recall¼Hopkins Verbal Learning Test recall after 30min; HVLT recog-
nition¼Hopkins Verbal Learning Test recognition after 30min; JLO¼ Judgment of Line
Orientation Test; LNS¼ Letter-Number Sequencing; PD ¼ Parkinson's disease;
SDMT¼ Symbol Digits Modalities Test. (For interpretation of the references to color in
this figure legend, the reader is referred to the Web version of this article.)
Fig. 3. Cortical thickness differences between groups at 2-cluster level.
Color maps indicate significant differences (corrected p< 0.05) between controls and PD subgroups.
Abbreviations: HC¼ healthy controls. Results were corrected by Monte Carlo simulation. (For interpretation of the references to color in this figure legend, the reader is referred to
the Web version of this article.)
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thinning in left postcentral gyrus and bilateral posterior superior
parietal, cuneus, and occipital gyri.
There were also cortical thickness differences between PD pat-
terns (Fig. 3). Patients in pattern 1 showed cortical thinning in right
orbitofrontal, right anterior cingulate, and bilateral anterior tem-
poral regions when compared with pattern 2 patients. Pattern 2
patients had cortical thinning in bilateral cuneus, precuneus, and
posterior superior parietal regions compared with pattern 1.
The two-cluster solutionwas selected because it had the highest
variance ratio (3.36) of the Calinski-Harabasz values. Three and
four-cluster solutions offered small cluster partitions and had
variance ratios of 2.85 and 2.55, respectively (Supplementary
Figure 3).
3.3. Clinical features of PD subtypes
PD patient subgroups showed no significant differences in
demographical variables when compared with HC. Patients in
pattern 2 scored significantly lower in the MoCA (U¼ 17.997;
P¼ 0.046) and scored higher in GDS-15 scale than HC (U¼ 20.340;
P¼ 0.015), and had more severe motor symptoms (U¼ 938.5;
P¼ 0.029) than pattern 1 patients as measured by the MDS-UPDRS
Part III. Both pattern 1 and 2 patients had more disability in ADL
(P1: U¼ 63.486; P< 0.0001; P2: U¼ 58.921; P< 0.0001) than HC as
measured by the MDS-UPDRS Part II. They also scored lower in the
UPSIT test (P1: U¼ 31.326; P< 0.0001; P2: U¼ 33.250; P< 0.0001)
and had a greater proportion of anosmic cases (P1: c2¼ 7.638;
P¼ 0.006; P2: c2¼ 7.693; P¼ 0.006) than the HC group (Table 1).
Both PD patterns had more impairment in global cognition
scores as measured with the MoCA< 26 (P1: c2¼ 7.539; P¼ 0.006;
P2: c2¼10.438; P¼ 0.001) than HC (Table 1). Regarding neuro-
psychological results (Fig. 2b), pattern 2 patients performed
significantly worse in HVLT-R total learning (F¼ 2.971; P¼ 0.055;
post hoc test: P¼ 0.050), HVLT-R delayed recall (F¼ 4.352;
P¼ 0.015; post hoc test: P¼ 0.013), and the Symbol Digits Modal-
ities Test (F¼ 6.056; P¼ 0.003; post hoc test: P¼ 0.002) than HC.
4. Discussion
To the best of our knowledge, this is the first study to distinguish
cortical atrophy patterns in early drug-naïve PD patients based on
objective brain imaging data. Two patterns were identified: one
with orbitofrontal, anterior cingulate and temporal atrophy, and
another involving occipital and parietal atrophy.Orbitofrontal involvement seen in Pattern 1 has not been pre-
viously described in de novo patients. There are previous studies
that reported cortical thinning in de novo patients in other regions
probably due to the different methodology used. These studies
classified patients a priori according to their cognitive status [3,18].
In these studies, patients with MCI had widespread atrophy
involving anterior and posterior regions. Pereira et al. [3] also found
cortical thinning in patients with normal cognition but restricted to
the right temporal cortex.
Despite showing cortical thinning in orbital regions, pattern 1
patients had no detectable neuropsychological impairments. This
could be explained by the lack of tests sensitive to orbitofrontal
functions in the PPMI battery, such as facial emotion recognition
tasks, which we previously found to be correlated with gray matter
reduction in these structures in PD patients [6,19].
In addition, we identified a region of cortical thickening in right
cuneus in Pattern 1 patients compared to controls. No previous
studies reported gray matter increases in early unmedicated PD
patients; this phenomenon was only identified in certain studies
raising a debate about a possible plastic effect of long term L-LDOPA
administration [20], and therefore would not correspond to the
clinical status of our patient sample. Increased cortical thickness in
temporo-parietal regions and in precuneus and posterior cingulate
was described in asymptomatic mutation carriers of presenilin 1
gene mutation compared with controls. This finding has been
interpreted as initial neuroinflammation [21].
Pattern 2 was characterized by atrophy in occipital and parietal
regions. Similar parietal thinning has also been described in PD-
MCI de novo patients [3]. Our sample was not classified a priori
according to cognitive status, but 32% of cases had MCI. Moreover,
pattern 2 patients had a neuropsychological profile of semantic
memory impairment that agrees with the thinning of posterior
cortical regions as previously reported [14]. The finding of cortical
thinning in the primary occipital cortex at the time of diagnosis is
noteworthy. It could underlie the color deficits described in mani-
fest PD and even in prodromal stages [22].
Pattern 2 patients showed impaired performance in HVLT-R
total learning, delayed recall, Symbol Digits Modalities Test, and
MoCA. Impairment in total learning and delayed recall have been
found to be good markers of future cognitive deterioration in PD
[23], and the Symbol Digits Modalities Test is a suitable marker of
cortical thinning in lateral temporo-parietal regions [24]. Posterior
cortical-based neuropsychological deficits have been related to
higher risk of evolution to dementia [25]. Pattern 2 patients seem to
show a worse cognitive phenotype, with greater proportion of MCI
Table 1
Demographic and clinical characteristics of PD subtypes.
PD patients HC (n¼ 50) Test stats P value
Pattern 1 (n¼ 33) Pattern 2 (n¼ 44)
Sex, male, n (%) 20 (60.6) 28 (63.6) 30 (60.0) 0.143a 0.931
Age, y, mean (SD) 61.7 (7.9) 64.2 (8.2) 62.3 (7.5) 1.084b 0.341
Education, y, median, (IQ) 16.0 (4.0) 16.0 (6.0) 16.0 (4.3) 0.677c 0.713
MoCA, median (IQ) 28.5 (3.0) 27.0 (3.0) 28.0 (2.0) 6.257c 0.044e
Disease duration, y, median (IQ) 1.0 (2.0) 1.0 (1.8) NA 705.5d 0.822
Age of onset, y, mean (SD) 60.7 (8.1) 63.3 (8.2) NA 852.5d 0.192
MDS-UPDRS part III, median (IQ) 19.0 (9.5) 24.0 (10.8) NA 938.5d 0.029
Hoehn & Yahr stage, n, 1/2/3 12/21/0 16/27/1 NA 0.766a 0.682
Motor subtype, n, tremor/PIGD/undetermined 25/3/5 31/10/3 NA 3.410a 0.182
GDS-15, median (IQ) 1.5 (3.0) 2.0 (4.0) 0.0 (1.0) 9.458c 0.009e
Depression, n (%) 6 (18.8) 3 (7.0) 5 (10.0) 2.678a 0.262
Apathy item MDS-UPDRS Part I, n (%) 11 (33.3) 6 (13.6) 2 (4.0) 13.538a 0.001
Subjective cognitive decline item MDS-UPDRS Part I, n (%) 11 (33.3) 12 (27.3) 7 (14.0) 4.616a 0.099
UPSIT, median (IQ) 22.0 (9.0) 20.0 (12.0) 35.5 (4.0) 33.779c <0.0001f
Anosmia, n (%) 9 (39.1) 12 (37.5) 2 (7.1) 8.94a 0.011
Schwab and England scale, median (IQ) 90.0 (8.0) 95.0 (10.0) NA 866.0d 0.125
MDS-UPDRS Part II, median (IQ) 7.0 (5.5) 5.0 (5.8) 0.0 (0.0) 86.838c <0.0001f
Total MCI, n (%) 7 (21.9) 14 (31.8) 3 (6.0) 10.340a 0.006
Global cognition impaired, n (%) 6 (18.8) 10 (22.7) 0 (0.0) 12.322a 0.002
Visuospatial functions, n (%) 4 (12.9) 4 (9.5) 4 (8.0) 0.526a 0.769
Executive functions, n (%) 3 (9.4) 3 (6.8) 2 (4.1) 0.925a 0.630
Memory, n (%) 5 (16.1) 16 (38.1) 7 (14.0) 8.575a 0.014
Attention and WM, n (%) 2 (6.5) 6 (14.3) 1 (2.0) 5.126a 0.077
Abbreviations: GDS-15¼Geriatric Depression Scale shortened version; HC¼Healthy Controls; IQ¼ interquartile range; MCI¼Mild Cognitive Impairment; MMSE¼Mini-
Mental State Examination; NA¼ not applicable; PD¼ Parkinson's disease; PIGD¼ Postural Instability Gait Difficulty; MDS-UPDRS¼Movement Disorders Society Unified
Parkinson's Disease Rating Scale; UPSIT¼University of Pennsylvania Smell Identification Test; WM ¼ Working Memory.
Global cognition impairment was established from the cut-off < 26 in MoCA test. Visuospatial, executive, memory and attention WM impairment was establish from the
number of subjects with at least one test impaired in each domain.
Data are presented as mean (SD) or median (IQ) for continuous variables as appropriate or frequencies for categorical.
a The Chi-squared test was used.
b Analysis of variance test was used.
c Kruskal-Wallis test was used.
d Mann-Whitney U test was used.
e Significant differences were found between HC and pattern 2 using pairwise Mann-Whitney test. P-values are given in the text.
f Significant differences were found between HC and both patterns using pairwise Mann-Whitney test. P-values are given in the text.
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pattern is similar to that identified in our previous study using
hierarchical cluster analysis in more advanced and medicated PD
patients [6].
Pattern 2 patients also had more severe motor symptoms. The
results from previous studies seem to show that PD patients with
predominant resting tremor at onset have a more benign disease
course and slower progression compared with those with a
postural instability and gait difficulty (PIGD) dominant subtype.
PIGD variant is commonly associated with a faster rate of cognitive
decline, higher prevalence of non-motor symptoms, and faster
progression [5]. In light of the aforementioned findings, we would
expect that pattern 2 patients, with higher rates of MCI, would be
related to a predominantly non-tremoric subtype. However, our
results showed that, although Pattern 2 showedmore severe motor
symptoms, the two patient groups did not differ in the proportion
of motor subtypes. The instability of motor-feature diagnosis in the
first year of the disease might explain the lack of predominance in
motor subtyping in this sample of de novo PD patients [26]. On the
other hand, previous studies showed an association between
cognitive dysfunction and clinical phenotypes, such as anosmia.
Fullard et al. [27] related the presence of severe olfactory deficits to
worse cognitive impairment in untreated PD patients, using PPMI
data. Nevertheless, we did not observe differences either in the
proportion of anosmia or the UPSIT score between the patient
groups. Longitudinal studies could clarify the evolution of these
patterns; clearer clinical phenotypes based on motor subtypes or
non-motor symptoms would be expected to be identified in more
advanced stages of the disease. Future studies could thus clarify therelationship between the identified patterns of atrophy and other
PD symptomatology.
In the present study, we did not find a non-atrophic group as
found in other studies with newly-diagnosed drug-naïve PD pa-
tients [28,29] or evenwith medicated patients with more advanced
disease [6,30e32]. This could be explained by the high sensitivity of
our methodological approach to detect subtle differences between
patients and HC. We improved the cluster analysis technique using
the HCP-MMP1.0 to perform a feature reduction of the imaging
data. In the last few years, there has been an increased interest in
the potential of machine learning techniques due to their ability to
manage large amounts of data, and because they allow hypotheses
to be guided by data itself using unsupervised approaches. None-
theless, clustering algorithms perform better when data sets avoid
multicollinearity and the curse of dimensionality. This method
seems to be sensitive for detecting subtle cortical atrophy even at
early stages of the disease, although further studies are needed to
replicate these results. In addition, unsupervised machine learning
techniques allowed us to detect PD subtypes from a hypothesis-free
data driven approach using objective imaging data rather than
clinical data that is examiner-dependent. The use of objective data
is especially relevant in multicenter studies, in which there is
increased variability of data collection.
One strength of this study is the use of a multicenter cohort of
patients from the PPMI data base with a large sample of HC, well-
matched with patients regarding age and education. Another
strength is that the sample of PD patients is very homogeneous, as
it is composed of de novo and untreated subjects. Despite this ho-
mogeneity on several variables (such as age, time of evolution, and
C. Uribe et al. / Parkinsonism and Related Disorders 50 (2018) 3e98clinical severity) we were able to detect subtypes of cortical thin-
ning and neuropsychological profile.
The limitations include the short neuropsychological battery
that did not allow using level II criteria to diagnose PD-MCI, and the
fact that MRI acquisitions were acquired at different research
centers (although all scanners were similar and acquisition pro-
tocols were standardized). In addition, the PPMI is a research cohort
with highly educated participants that might not be representative
of the general population. The PPMI sample have scarce cognitive
or psychiatric symptoms at baseline, restricting the use of corre-
lational approaches with neuroimaging findings. We would also
like to highlight the complexity of PD diagnosis at early stages of
the disease. Patients were selected based on neuroimaging evi-
dence of significant dopamine transporter deficit consistent with
the clinical diagnosis of PD and ruling out PD look-alike conditions
such as drug-induced and vascular parkinsonism or essential
tremor. However, certain diagnoses can only be established by
pathological findings.
To sum up, two different cortical atrophy patterns can be
identified at the time of diagnosis in unmedicated PD patients. Our
results establish a starting point to investigate the evolution of
these patterns as possible useful markers of clinical prognosis.
Moreover, the MRI findings indicate the necessity to review the
neuropsychological tests included in cohort studies trying to cover
the functional assessment of all cortical regions that have been
found to be impaired in PD.
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